Complexities of HCV management in the new era of direct-acting antiviral agents

Rosenberg, W.M.; Tanwar, S.; Trembling, P.
January 2014
QJM: An International Journal of Medicine;Jan2014, Vol. 107 Issue 1, p17
Academic Journal
The availability of the direct-acting antiviral agents (DAAs) boceprevir and telaprevir provides improved treatment outcomes for many patients infected with hepatitis C virus (HCV) genotype 1. However, HCV infection must first be identified before a decision on treatment can be made and currently many patients remain unaware that they have the virus. Given the lack of prompt diagnosis, disease severity should be determined as a baseline reference for treatment, and novel non-invasive techniques for evaluating fibrosis are now available. For patients receiving a DAA regimen, response-guided therapy based on the detection, absence or level of HCV RNA at specified time points is required to achieve an optimal treatment outcome. Knowledge of the test used to measure HCV RNA and its analytical sensitivity, as well as how to interpret the results correctly, are therefore required to administer therapy appropriately. Furthermore, effective treatment management includes appropriate handling of side effects. This increased complexity associated with DAA regimens has resulted in confusion over many aspects of care, including treatment monitoring, viral load result interpretation and the optimal duration of therapy. These issues are discussed here in addition to the benefits of referring patients infected with HCV to a specialist centre.


Related Articles

  • Vascular endothelial growth factor mRNA expression can be a marker for response to antiviral treatment of HCV. El-Gohary, Ahmed; Attia, Fadia; Eldin, Abeer; Hassen, Adel; Nemer, Nader; Kalil, Fawzy // Comparative Clinical Pathology;Jul2014, Vol. 23 Issue 4, p923 

    Angiogenesis has a significant pathogenic role in liver damage-associated hepatitis C virus infection. We evaluated whether chronic hepatitis C (CHC) is associated with elevated levels of angiogenesis marker (vascular endothelial growth factor) and whether it is modulated by therapy. Vascular...

  • Advice on using DAAs for patients with HCV/HIV coinfection. Dieterich, Douglas T. // Research Initiative/Treatment Action!;Summer2014, Vol. 19 Issue 1, p15 

    An interview with Douglas T. Dieterich, professor of medicine at Icahn School of Medicine at Mount Sinai in New York City, is presented. Topics discussed include DAA (direct-acting antivirals) research done in hepatitis C virus (HCV)/HIV-coinfected people, treatment of HIV-coinfected people with...

  • HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy. Kazuaki Chayama; Hayes, C. Nelson // Viruses (1999-4915);2015, Vol. 7 Issue 10, p5328 

    Sustained virological response (SVR) rates have increased dramatically following the approval of direct acting antiviral (DAA) therapies. While individual DAAs have a low barrier to resistance, most patients can be successfully treated using DAA combination therapy. However, DAAs are vulnerable...

  • Results of antiviral treatment of patients with chronic hepatitis C: experience of Poznan centre. Bura, Maciej; Kowala-Piaskowska, Arleta; Adamek, Agnieszka; Bura, Aleksandra; Czajka, Arkadiusz; Hryckiewicz, Katarzyna; BereszyƄska, Iwona; Mozer-Lisewska, Iwona // Advances in Hygiene & Experimental Medicine / Postepy Higieny i ;2012, Vol. 66, p339 

    Introduction: Hepatitis C virus (HCV) infection in Poland affects approximately 750 thousand persons. The prevention of cirrhosis and hepatocellular carcinoma, of which approximately 20% of patients with chronic hepatitis C virus are at risk, aims at eradication of the virus by applying...

  • Success of antiviral therapy in chronic hepatitis C infection relates to functional status of myeloid dendritic cells. Deepa Rana; Yogesh Chawla; Arora, Sunil K. // Indian Journal of Medical Research;Nov2013, Vol. 138 Issue 5, p766 

    Chronic hepatitis C infection poses a major global health predicament and appears to be potent threat to mankind. The treatment in wide use is interferon/ribavirin combination therapy which is generally effective in about 60-70 per cent of patients carrying genotype 3 and causes significant...

  • Real-world Experience with Sofosbuvir-based Regimens for Chronic Hepatitis C, Including Patients with Factors Previously Associated with Inferior Treatment Response. Wu, Christina J.; Roytman, Marina M.; Hong, Leena K.; Huddleston, Leslie; Trujillo, Ruby; Cheung, Alvin; Poerzgen, Peter; Tsai, Naoky C. S. // Hawaii Journal of Medicine & Public Health;2015 Supplement, Vol. 74, p3 

    The introduction of sofosbuvir, a direct acting antiviral, has revolutionized the treatment of chronic hepatitis C virus (HCV). Phase 3 clinical trials have demonstrated the efficacy, simplicity, and tolerability of sofosbuvir-based regimens and report high rates of sustained virological...

  • Enhancing Assessment and Treatment of Hepatitis C in the Custodial Setting. Post, Jeffrey J.; Arain, Amber; Lloyd, Andrew R. // Clinical Infectious Diseases;Aug2013, Vol. 57 Issue Supp 2, pS70 

    Acute and chronic hepatitis C (HCV) infections are prevalent in custodial settings worldwide, yet provision of antiviral therapies is uncommon. This disparity between the burden of disease and hepatitis service delivery reflects the marginalized patient population, which features high rates of...

  • Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent. Kwon, Hyock Joo; Xing, Weimei; Chan, Katie; Niedziela-Majka, Anita; Brendza, Katherine M.; Kirschberg, Thorsten; Kato, Darryl; Link, John O.; Cheng, Guofeng; Liu, Xiaohong; Sakowicz, Roman // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Ledipasvir, a direct acting antiviral agent (DAA) targeting the Hepatitis C Virus NS5A protein, exhibits picomolar activity in replicon cells. While its mechanism of action is unclear, mutations that confer resistance to ledipasvir in HCV replicon cells are located in NS5A, suggesting that NS5A...

  • The Hepatitis C Virus Replicase: Insights into RNA-dependent RNA Replication and Prospects for Rational Drug Design. Frick, David N. // Current Organic Chemistry;Feb2004, Vol. 8 Issue 3, p223 

    The enzymes involved in the replication of the Hepatitis C Virus (HCV) have been some of the most intensely studied proteins in recent history because they are targets for rational drug design. HCV is an established and growing menace to human health that is without a current vaccine or a widely...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics